by CheckRare Staff | Feb 1, 2024
Cat Lutz, PhD, MBA, Vice President of the JAX Rare Disease Translational Center, discusses rare disease research’s impact on understanding common diseases. Developing therapeutics for rare diseases come with their own set of unique challenges and...
by CheckRare Staff | Jan 30, 2024
Andy Udell, President of Calliditas Therapeutics North America, discusses current IgA nephropathy treatment options (including Tarpeyo [budesonide]) and the Phase 3 NefIgArd trial. Immunoglobulin A (IgA) nephropathy is a rare, autoimmune, kidney disorder...
by CheckRare Staff | Jan 29, 2024
Hesham Abdullah, MD, MSc, of GSK, discusses myelofibrosis treatment options, including recently approved Ojjaara (momelotinib). Transcription: My name Hesham Abdullah, senior vice president, global head of oncology within R&D at GSK. So I oversee...
by CheckRare Staff | Jan 27, 2024
Doris Hansen, MD, Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy, discusses the treatment of multiple myeloma using daratumumab, lenalidomide, and dexamethasone (D-Rd) and bortezomib, lenalidomide,...
by CheckRare Staff | Jan 26, 2024
Cheryl Schwartz, SVP of Takeda U.S. Rare Disease Business Unit, discusses Takeda’s report that calls for enhanced health equity and timely diagnosis for rare disease patients. She also talks about Takeda’s main focuses and their partnership with NORD, as...
